The initial euphoria over the GLP-1 drugs like Ozempic has mellowed, but catalysts expected in 2025 could energize investor interest in the stocks.
Related Posts
Asia-Pacific markets trade mixed as investors parse Japan’s downbeat GDP data
Hong Kong and Malaysia are also set to report GDP data later in the day.
Bezos’ Blue Origin stands down on debut launch of New Glenn rocket
Jeff Bezos’ Blue Origin called off the inaugural launch of its key New Glenn rocket following last-minute issues on the vehicle.
Adidas warns it will raise prices on all U.S. products due to tariffs
“Higher tariffs will eventually cause higher costs for all our products for the US market,” Adidas said in a statement.